Executive Summary
2,407 candidates evaluated. 287 strong matches. 47 shortlisted by you.
Week 1 took your search from a blank graph to a fully-instrumented sourcing engine. We ran a series of targeted hunts shaped around your shortlist signal, fed every profile through a calibrated AI gate built against your first 30 yeses, and surfaced the daily release queue you've been working through.
The week confirmed three things: distributor-shaped hunts yield ~4× better than broad manufacturer searches, IC titles are the right priority over Director/VP, and the “pivot path” pattern (big-pharma reps moving to aesthetics) is a high-signal pocket we haven't yet hunted. Week 2 opens that pocket.
Week 1 By the Numbers
2,407
Profiles Analyzed
412
Companies Mapped
287
LLM 4/4 Matches
47
Shortlisted by You
575
Pending Your Review
848
Filter-Rejected
196
Released to You
100%
AI Gate Coverage
Reading the funnel.
For every 100 profiles ingested, ~12 score 4/4 strong, ~12 more land good_fit/worth_investigating, and ~35 are auto-rejected by hard filters before they ever reach you. The remaining ~41 are mid-tier (1-2/4) sitting in reserve for re-gate as criteria evolve.
Pipeline Funnel
How 2,407 raw profiles became 47 shortlisted
Profiles ingested
2,407
100%
Passed hard filters
1,559
65%
LLM-graded 1+/4
585
24%
LLM-graded 4/4
287
12%
Released to your queue
196
8%
Shortlisted by you
47
2%
Roughly 1 in 4 of what we surfaced to you this week made your shortlist. The funnel above is the lens we use to decide where to invest next week.
Search Brief — What We're Calibrated To
The pattern we built against
This is what every candidate gets graded on. If anything below is wrong or stale, flag it and we re-gate the entire graph against the new spec by Tuesday.
- Niche
- 1099 medical sales reps — peptides, regenerative medicine, aesthetics injectables, biologics
- Tier 1 fit
- Currently selling into med spas / dermatology / antiaging clinics on a 1099 basis with existing book
- Tier 2 fit
- Orthopedics or spine reps, biologics, healthcare-adjacent (oncology, rare disease, pharma) with healthcare sales pedigree
- Hard rejects
- Clinic owners · D2C/patient-facing · W-2 lifers · Non-aesthetics pharma generalists · Author/coach personas · Non-US territory
- Saturated companies
- BENEV (excluded) · Current-Merz (hard reject — past-Merz fine)
- Title preference
- IC and Manager preferred; Director/VP capped at ~10% of daily batches
- Geo focus
- US-only · Sun Belt prioritized (TX, CA, FL, AZ) · Denver/Ohio deprioritized
- Daily volume
- ~50 per release queue, ~10-15 expected to land in shortlist
TAM Graph Expansion
Your total addressable market, mapped
The graph went from zero to 412 distinct employers and 2,407 named individuals in seven days. That's the shape of your TAM at the level of resolution we need to hunt against. Here's how it's distributed.
412
Distinct Employers
29
Reference Brands
11
Distributors
8
Compounding Pharmacies
Top 25 employers in your graph
Where the bulk of your future shortlist will come from. The "4/4 in graph" column is the unworked reservoir at each company — people who passed the LLM gate but haven't been released to you yet.
| Company | In Graph | LLM 4/4 | Yield | Type |
|---|---|---|---|---|
| Revance | 82 | 40 | 49% | Reference brand |
| Merz Aesthetics | 68 | 7 | 10% | Saturated |
| EVEXIAS Health Solutions | 51 | — | — | Peptide / hormone |
| Aesthetic Management Partners | 85 | 33 | 39% | Distributor |
| Tiger Aesthetics | 64 | 16 | 25% | Distributor |
| Collagen P.I.N. / Induction Therapies | 36 | — | — | Reference brand |
| Prollenium | 31 | 19 | 61% | Reference brand |
| Evolus | 30 | 11 | 37% | Reference brand |
| Cartessa Aesthetics | 28 | 14 | 50% | Reference brand |
| Strive Compounding Pharmacy | 27 | — | — | Compounding pharmacy |
| Rohrer Aesthetics | 26 | 10 | 38% | Distributor |
| AbbVie | 20 | 5 | 25% | Reference brand |
| Galderma | 19 | 11 | 58% | Reference brand |
| Rion Aesthetics | 19 | 3 | 16% | Reference brand |
| Loria Medical | 18 | — | — | Reference brand |
| Epionce / Episciences | 16 | 3 | 19% | Reference brand |
| REVIAN | 15 | — | — | Reference brand |
| Hydrafacial | 15 | 11 | 73% | Reference brand |
| Aesthetic Partners | 15 | — | — | Distributor |
| Allergan Aesthetics | 13 | 8 | 62% | Reference brand |
| Apyx Medical | 13 | 10 | 77% | Reference brand |
| 180 Health Services | 11 | 7 | 64% | Distributor |
| Allergan | 11 | 8 | 73% | Reference brand |
| AnteAGE | 10 | 8 | 80% | Reference brand |
| TRU Biologix | 10 | — | — | Biologics |
Plus 387 more companies with 1-9 reps each. Full breakdown available in the Reach data center under Companies → By tenant.
Untapped reservoir at your shortlist-aligned companies: 148 LLM 4/4 candidates.
That's roughly 3 days of 50-candidate batches sitting ready before we need to scrape new sources. Top reservoirs: Revance (29), AMP (17), Tiger (12), Rohrer (12), Hydrafacial (11), Evolus (10), Apyx (9), Cartessa (9).
What We Now Know
Six findings we couldn't have known on Day 0
01
Distributors yield 4× more 1099-quality reps than manufacturer scrapes.
Distributor-shaped hunts (AMP, Rohrer, Tiger, 180 Health) produced 49% strong-match yield. Broad manufacturer/brand searches produced only 17%. The reason is structural: distributors' business model is 1099 multi-line reps, while manufacturers mostly carry W-2 territory managers. Week 2 leans further into the distributor angle.
+ Higher-quality candidates per hour, less noise in your queue
02
IC titles outperform Director/VP — verified against your shortlist.
Your 47 shortlisted candidates break down: 63% IC, 23% Manager, 5% Director, 2% VP, 7% NULL. We've baked this into the gate as a soft cap: Director/VP candidates are now limited to ~10% of daily batches. 12 Director/VPs were quietly swapped out of last Friday's queue and replaced with IC reservations from Apyx and Hydrafacial.
+ Estimated ~5pp lift in your shortlist rate
03
Sun Belt territories dominate your shortlist.
Geo clusters in your shortlist: Birmingham (3), San Diego (3), Las Vegas (3), Dallas / DFW (6), Charleston SC (2), St. Petersburg (2), Newport Beach (2), Atlanta (2), San Antonio (2), Ft. Lauderdale (2). Together TX/CA/FL/AZ account for 60%+ of shortlists. Confirms your earlier read that aesthetics 1099 work concentrates where the cash-pay clinic density is highest.
04
A “pivot path” pattern emerged we haven't hunted yet.
Your shortlist contains repeated alumni signal from outside aesthetics: SkinCeuticals (2), Smith & Nephew (2), Integra LifeSciences (2), Takeda (2), Bristol-Myers Squibb (2), Endo Aesthetics (2). These are reps who pivoted from big-pharma / med-device into aesthetics. Currently 0 of those companies are in our graph. Week 2 opens a dedicated hunt against this lateral-move pattern.
Untapped pocket — expect ~80-120 net-new 4/4s
05
Hard-reject filters are doing real work — 848 dispositioned before reaching you.
Top red flags triggered: non-aesthetics pharma (142), clinic owners (127), W-2 exclusive (113), D2C / patient-facing (84), current-Merz (56), author/speaker/coach (19), non-US territory (7). Without these gates you'd be reviewing 848 more profiles a week, most of them junk. The gate is calibrated against your “yes” and “no” feedback from the first 30 candidates.
~13 hours of manual review saved this week alone
06
BENEV is saturated — hard-excluded after your feedback.
44 BENEV-tagged candidates marked excluded-saturated based on your call. The exclusion is enforced at scrape time and at queue time so they don't slip in via similar-people expansion. Past-BENEV alumni still considered (and often shortlist-quality).
Your Shortlist, by Source
Where your 47 yeses came from
Your shortlist composition is the ground truth for calibrating next week's hunt. Companies that show up here are the ones we double-down on.
| Current Employer | Shortlisted | % of List | Read |
|---|---|---|---|
| Merz Aesthetics | 6 | 13% | Past-Merz only — current=reject |
| Revance | 5 | 11% | Anchor company |
| Aesthetic Management Partners | 5 | 11% | Distributor angle working |
| Allergan Aesthetics | 4 | 9% | Anchor company |
| Evolus | 3 | 6% | Reference brand |
| Tiger Aesthetics | 3 | 6% | Distributor |
| BENEV | 2 | 4% | Saturated — new excluded |
| Prollenium / AnteAGE | 2 ea | 4% ea | Reference brand |
| Long-tail (1 each × 16 firms) | 16 | 34% | Diverse / niche |
Calibration check.
34% of your shortlist sits in the long tail (1-of-1 employers). That's healthy — you're not over-anchored on Revance/Allergan. But it also means we have to keep widening the hunt, not just deepen the top 10.
Filter Calibration
What the gate filtered out
These are the red-flag categories we flagged and rejected before they reached your queue. If any of these shouldn't be hard rejects, tell us — we recalibrate the gate.
| Red Flag | Triggered | Logic |
|---|---|---|
| non_aesthetics_pharma | 142 | Generalist big-pharma rep with no aesthetics signal in bio |
| clinic_owner | 127 | Owns/runs a med spa — buyer side, not sell side |
| current_employer_w2_exclusive | 113 | Currently W-2 at a non-multi-line firm; unlikely to take 1099 |
| d2c_patient_facing | 84 | Sells direct to patients (esthetician, nurse injector) |
| current_employer_merz | 56 | Active Merz — per your feedback, hard-reject |
| author_speaker_coach | 19 | Mostly content/training revenue, not field sales |
| non_us_territory | 7 | Outside US sales territory |
What's Working
Strengths to keep doing
01
Daily release queue is running steadily at ~50/day.
Average ~50 candidates released per day, with shortlist activity carrying through the week. Cadence is stable enough to plan the next week's hunt against.
02
AI gate v2 (calibrated against your 30 yeses) is holding up.
Of 196 candidates released this week, 47 made shortlist. The gate is filtering out the obvious mismatches before they hit your queue, which is the point — whether the conversion rate is the right one is your call.
03
Per-person evidence (“why they fit”) eliminates the cold-read problem.
Every released candidate now ships with a per-person reasoning string from the LLM (“currently selling Hydrafacial in Austin, prior Allergan rep, has aesthetics-only territory”). No more scanning a LinkedIn URL cold — the reasoning is right next to the name.
Next Week's Plan
Two moves for Week 2
Both tie back to what we learned this week. The first sharpens the queue you already see; the second widens the pool feeding into it.
MOVE 1
Raise the shortlist conversion rate.
Tighten the AI gate against the patterns your 47 yeses share — weight up the Sun Belt geo signal, weight up IC titles further, weight up distributor-aligned current employers, weight down compounding-pharmacy-only profiles that haven't been converting. Re-grade the existing graph against the new weights so reservoir candidates resurface with sharper rankings.
Target: lift your shortlist rate from ~24% to 30%+ on Week 2 releases
MOVE 2
Expand the total addressable market.
Open two adjacent pockets we haven't hunted yet. First: deeper coverage at the manufacturer-reference brands you've shortlisted from but where our graph is thin (Revance, Evolus, Prollenium, Cutera, Solta, Sciton, Apyx, Crown Aesthetics, Letybo, plus medical-grade skincare like SkinCeuticals, Obagi, ZO, SkinMedica, Alastin, iS Clinical). Second: the “pivot path” cohort — reps who came from big-pharma / med-device (Smith & Nephew, Integra LifeSciences, Takeda, BMS, Endo) into aesthetics. Currently 0 in your graph, but multiple shortlisted candidates fit this pattern.
Expected: +360-470 net-new strong matches added to your graph
Calibration Check
Five questions. Five minutes. Saved straight to your account.
Your answers feed directly into next week's AI gate. No emailing, no dashboards — click an answer, hit submit, and the search recalibrates.